Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INNOVIVA, INC.

(INVA)
  Bericht
Verzögert Nasdaq  -  22:00:01 01.02.2023
12.75 USD   +0.79%
04.01.Innoviva, Inc. gibt die Ernennung von Sapna Srivastava zum Mitglied des Board of Directors bekannt
CI
2022Innoviva, Inc. gibt bekannt, dass die FDA den Antrag auf ein neues Arzneimittel für Sulbactam-Durlobactam angenommen und vorrangig geprüft hat
CI
2022Innoviva, Inc. (NasdaqGS:INVA) kündigt einen Aktienrückkauf im Wert von $100 Millionen an.
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über INNOVIVA, INC.
11.01.Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agre..
04.01.Innoviva, Inc. : Change in Directors or Principal Officers, Amendments to Articles of Inc...
04.01.Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors
2022Innoviva Says FDA Accepts, Grants Priority Review for Infection Treatment SUL-DUR NDA
2022Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulba..
2022Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for ..
2022Innoviva : Q3 Earnings Snapshot
2022INNOVIVA, INC. Management's Discussion and Analysis of Financial Condition and Results..
2022Innoviva, Inc. announces an Equity Buyback for $100 million worth of its shares.
2022Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Pro..
2022Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
2022Innoviva, Inc. authorizes a Buyback Plan.
2022INNOVIVA, INC. Completion of Acquisition or Disposition of Assets, Financial Statement..
2022Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safe..
2022Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR ..
2022Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Ora..
2022Nanolive SA announced that it has received $22.2 million in funding from Taiwania Capit..
2022Innoviva, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
2022Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022Innoviva : A. Risk Factors - Form 8-K
2022Innoviva, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022Innoviva : Completion of Acquisition or Disposition of Assets - Form 8-K
2022Innoviva, Inc. : Completion of Acquisition or Disposition of Assets, Other Events, Financi..
2022Innoviva Completes Acquisition of La Jolla Pharmaceutical
2022Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La ..
2022INNOVIVA, INC. Management's Discussion and Analysis of Financial Condition and Results..
2022Innoviva : Q2 Earnings Snapshot
2022Innoviva : Reports Second Quarter 2022 Financial Results and Highlights Recent Company Pro..
2022Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Pr..
2022Earnings Flash (INVA) INNOVIVA Posts Q2 Revenue $108.2M
2022Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
2022Innoviva, Inc. : Entry into a Material Definitive Agreement (form 8-K)
2022Royalty Pharma plc completed the acquisition of 15% stake in Theravance Respiratory Com..
2022Royalty pharma agrees to acquire royalty interest in trelegy ellipta from theravance an..
2022Innoviva, Inc. : Entry into a Material Definitive Agreement, Other Events, Financial State..
2022Innoviva Selling Minority Stake in Asthma Therapies Company; Shares Rising in After-Hou..
2022Innoviva Reportedly Sells 15% Stake In Theravance Respiratory Company, Bloomberg Says
2022Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma f..
2022Royalty Pharma plc entered into an agreement to acquire 15% stake in Theravance Respira..
2022Innoviva Acquires Remaining Stake in Entasis Therapeutics
2022Innoviva : Completes Acquisition of Entasis Therapeutics - Form 8-K
2022Innoviva, Inc. : Completion of Acquisition or Disposition of Assets, Other Events, Financi..
2022Sector Update: Health Care Stocks Edging Lower at Close
2022Top Midday Gainers
2022Sector Update: Health Care Stocks Still Little Changed
2022Sector Update: Health Care
2022Innoviva Agrees to Take La Jolla Pharmaceutical Private in $149 Million Acquisition Dea..
2022Innoviva Completes Acquisition of Entasis Therapeutics
2022Innoviva : to Acquire La Jolla Pharmaceutical Company - Form 8-K
2022Innoviva, Inc. : Entry into a Material Definitive Agreement, Other Events, Financial State..
2022Innoviva to Acquire La Jolla Pharmaceutical Company
2022Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeu..
2022Innoviva, Inc. (NasdaqGS:INVA) entered into a definitive merger..
2022Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics H..
2022Innoviva, Inc.(NasdaqGS:INVA) added to Russell 2000 Dynamic Inde..
2022Innoviva, Inc.(NasdaqGS:INVA) dropped from Russell 2000 Value-De..
2022Innoviva, Inc.(NasdaqGS:INVA) dropped from Russell 3000 Value In..
2022Innoviva, Inc.(NasdaqGS:INVA) dropped from Russell 3000E Value I..
2022Innoviva, Inc.(NasdaqGS:INVA) dropped from Russell 2500 Value In..
2022Innoviva, Inc.(NasdaqGS:INVA) dropped from Russell Small Cap Com..
2022Innoviva, Inc.(NasdaqGS:INVA) dropped from Russell 2000 Value In..
2022Innoviva : TENDER AND SUPPORT AGREEMENT - Form 8-K
2022Innoviva, Inc. : Entry into a Material Definitive Agreement, Other Events, Financial State..
2022Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash..
2022Innoviva to Acquire Entasis Therapeutics
2022Innoviva to Acquire Entasis Therapeutics
2022INNOVIVA, INC. Management's Discussion and Analysis of Financial Condition and Results..
2022INNOVIVA, INC. Change in Directors or Principal Officers (form 8-K/A)
2022Innoviva, Inc. : Change in Directors or Principal Officers, Financial Statements and Exhib..
2022Innoviva, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
2022Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Busine..
2022Innoviva : Reports First Quarter 2022 Financial Results - Form 8-K
2022Innoviva : Q1 Earnings Snapshot
2022Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $90.1M
2022Innoviva Reports First Quarter 2022 Financial Results
2022Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Innoviva, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
2022Nanolive SA announced that it expects to receive funding from Taiwania Capital Manageme..
2022Innoviva, Inc. : Entry into a Material Definitive Agreement (form 8-K)
2022Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Pri..
2022Innoviva, Inc. : Changes in Registrant's Certifying Accountant, Financial Statements and E..
2022Innoviva, Inc. : Entry into a Material Definitive Agreement, Creation of a Direct Financia..
2022Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides..
2022Innoviva : Announces Proposed Offering of $200 Million of Convertible Senior Notes - Form ..
2022Innoviva, Inc. : Entry into a Material Definitive Agreement, Creation of a Direct Financia..
2022Innoviva Increases 2.125% Convertible Senior Notes Offering to $225 Million
2022Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Not..
2022Innoviva Plans Private Offering of $200 Million of Convertible Senior Notes
2022Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
2022INNOVIVA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
2022Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the C..
2022Innoviva : Q4 Earnings Snapshot
2022Innoviva : Reports Fourth Quarter 2021 Financial Results - Form 8-K
2022Innoviva, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
2022Innoviva Reports Fourth Quarter 2021 Financial Results
2022Innoviva, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
2022Entasis Therapeutics Receives Cash Buyout Proposal From Innoviva at $1.80/Share; Shares..
2022Innoviva, Inc. entered into a definitive agreement to acquire to acquire remaining 40% ..
2021Innoviva, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
2021Armata Pharmaceuticals Secures $7 Million Investment From Cystic Fibrosis Foundation, I..